Advaxis is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes . The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.The Lm-based platform on which the company's products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patient's immune system to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.The Company also has a veterinary medicine program that is evaluating an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. Source: www.advaxis.com Wikipedia.
Advaxis | Date: 2015-04-14
The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.
Advaxis and U.S. National Institutes of Health | Date: 2015-03-05
The present invention is directed to methods for increasing T-cell effector cell to regulatory T cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and tumor-associated antigen.
Advaxis, University of Pennsylvania and Foundation University | Date: 2016-07-27
This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
University of Pennsylvania and Advaxis | Date: 2015-07-01
The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest.
Advaxis and University of Pennsylvania | Date: 2015-02-25
This invention provides compositions and methods for treating and vaccinating against a HER2/neu antigen-expressing tumor and inducing an immune response against the same in a subject.
Advaxis and University of Pennsylvania | Date: 2015-07-01
This invention provides compositions and methods for treating and vaccinating against a Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a human subject.
University of Pennsylvania and Advaxis | Date: 2015-04-15
A recombinant Listeria strain expressing a kallikrein-related peptidase 3 (KLK3) peptide, wherein the sequence of the KLK3 peptide comprises a sequence selected from SEQ ID NOs: 27, 29-32, 34, and 36-39, or a sequence greater than 95% identical thereto, wherein the KLK3 peptide is in the form of a fusion peptide and further comprises a non-KLK3 peptide, wherein the non-KLK3 peptide is an ActA peptide or a PEST sequence, and wherein the non-KLK3 enhances the immunogenicity of the fusion peptide.
Advaxis | Date: 2015-04-01
A recombinant Listeria strain expressing a fusion polypeptide, wherein the fusion polypeptide comprises a heterologous antigen fused to an N-terminal LLO, wherein the recombinant Listeria is an attenuated Listeria which comprises a mutation in the dal/dat genes, a metabolic enzyme that complements the dal/dat mutation, and a mutation or deletion of the endogenous actA gene, and medical uses thereof. The heterologous antigen may be Prostate Specific Antigen (PSA).
Advaxis | Date: 2016-02-03
The present disclosure provides methods of treating, protecting against, enhancing and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria. In other embodiments, the Listeria stimulates the STING pathway.
Advaxis and Merck And Co. | Date: 2015-07-17
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.